Please ensure Javascript is enabled for purposes of website accessibility

Why Brown-Forman, H&R Block, and Madrigal Pharmaceuticals Jumped Today

By Dan Caplinger - Dec 6, 2017 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out why the spirits giant saw a nice move higher.

The stock market was relatively quiet on Wednesday, as competing factors kept major benchmarks within a fairly tight range close to where they began the day. Ongoing progress on trying to reconcile the two different versions of the tax reform bill kept some investors happy, but a rise in geopolitical risk and ethics-related turmoil in Congress put a damper on sentiment. Nevertheless, some individual companies had positive news, and Brown-Forman (BF.A -6.85%) (BF.B -7.16%), H&R Block (HRB -2.12%), and Madrigal Pharmaceuticals (MDGL -4.31%) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.

Raise a glass to Brown-Forman's quarterly results

Shares of Brown-Forman were up 5%-6% after the maker of Jack Daniel's and other spirits reported its fiscal second-quarter financial results. The company said that revenue for the quarter jumped 10%, helping to send earnings higher by nearly a quarter compared to the previous year's fiscal Q2. Emerging markets were especially strong, benefiting from good organic performance and favorable currency moves, and the company's super-premium and ultra-premium categories showed faster growth than the overall business. With spirits becoming more popular among consumers at the expense of beer and wine, Brown-Forman is in an ideal position to take advantage of favorable industry conditions.

Two people in jeans pushing an oak barrel along the floor.

Image source: Brown-Forman.

H&R Block gets ready for tax season

H&R Block stock picked up 10% in the wake of the tax preparation specialist's financial report for its fiscal second quarter. H&R Block saw revenue rise 7% from year-ago levels, but the tax preparer's loss for the quarter widened slightly during the company's off-season. Nevertheless, H&R Block is optimistic about its future, believing that even if tax reform efforts to get through Congress, changes in the tax laws tend to boost its business. Investors have worried about the impact of reform on the tax preparer, but regardless of promises from the federal government for simplified returns, H&R Block is banking on continued complexity keeping customer coming into its doors.

Madrigal sees good study results

Finally, shares of Madrigal Pharmaceuticals soared almost 90%. The clinical-stage biopharmaceutical company announced that its MGL-3196 experimental treatment for non-alcoholic steatohepatitis showed statistically significant improvements in many key endpoints in a phase 2 clinical trial. Madrigal said that the drug resulted in decreased liver fat compared to the placebo, as well as more favorable low-density lipoprotein cholesterol counts and improved liver enzymes. The big question facing investors is whether Madrigal can compete against rivals that are both financially stronger and further along in development of treatments fighting this disease, but shareholders nevertheless seemed optimistic about the company's prospects.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

H&R Block, Inc. Stock Quote
H&R Block, Inc.
$33.33 (-2.12%) $0.72
Brown-Forman Corporation Stock Quote
Brown-Forman Corporation
$62.47 (-7.16%) $-4.82
Brown-Forman Corporation Stock Quote
Brown-Forman Corporation
$59.17 (-6.85%) $-4.35
Madrigal Pharmaceuticals, Inc. Stock Quote
Madrigal Pharmaceuticals, Inc.
$66.67 (-4.31%) $-3.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.